


## NVL-520

### ROS1

oral brain-penetrant ROS1-selective TKI  
Ph. I/II for NSCLC and other solid tumors  
rationally designed (SBDD) from known starting point

*Press Release*, September 2023

NUVALENT INC., CAMBRIDGE, MA




## GDC-1971 (RLY-1971)

### SHP2

oral allosteric SHP2 inhibitor  
Ph. I for advanced or metastatic solid tumors  
virtual screening with MD simulation based on known matter

*J. Med. Chem.*, September 2023

RELAY THERAPEUTICS, MA / GENENTECH, CA




## encalaret

### CaSR

oral CaSR antagonist (calcilytic)  
Ph. III for ADHI  
opt. from known starting point from HTS

*N. Engl. J. Med.*, September 2023

JAPAN TOBACCO, JP / CALCILYTIX, CA




## mezigdomide

### IKZF1/3

oral cereblon-based IKZF1/3 degrader  
Ph. III for relapsed and refractory multiple myeloma  
phenotypic and protein degradation screen vs. IKZF1 and 3

*N. Engl. J. Med.*, September 2023

CELGENE CORPORATION, SAN DIEGO, CA




## BMS-986172

### MGAT2

oral MGAT2 inhibitor  
Ph. I for obesity  
from opt. of previous clinical candidate (HTS on human MGAT2)

*J. Med. Chem.*, September 2023

BRISTOL MYERS SQUIBB COMPANY, NJ




## dalcetrapib

### CETP

CETP inhibitor thioester prodrug  
Ph. III for cardiovascular diseases  
repurposed HDL cholesterol modulator

*Press Release*, September 2023

JAPAN TOBACCO, JP / DALCOR, CA




## mavorixafor

### CXCR4

oral allosteric CXCR4 inhibitor  
Ph. III NDA for WHIM syndrome  
opt. from plerixafor

*Press Release*, September 2023

X4 PHARMACEUTICALS, BOSTON, MA




## tovorafenib (BIIB-024)

### RAF

oral CNS-penetrant selective type II pan-RAF inhibitor  
Ph. III for pediatric low-grade glioma (LGG)  
activity for LGG identified in cell-based screening of RAF inhibitors

*Press Release*, September 2023

BIOGEN / TAKEDA / DAY ONE




## AZD4604

### JAK1

inhalable JAK-1 selective inhibitor  
Ph. II for asthma  
opt. from oral JAK1 program (HTS of AstraZeneca collection vs. JAK1)

*J. Med. Chem.*, September 2023

ASTRAZENECA, GOTHENBURG, SE



## ABX-002

### TR-β

selective CNS-penetrant TR-β agonist prodrug  
Ph. II for major depressive disorder (MDD)  
CNS-penetrant prodrug from known TR-β agonist chemotype

*Press Release*, September 2023

AUTOBAHN THERAPEUTICS, SAN DIEGO, CA